Acrivon Therapeutics (ACRV) Corporate presentation summary

Strategic overview and technology platform

• Focus on next-generation precision medicine using the AP3 proteomics platform for rational drug design and clinical development, initially targeting oncology with expansion into inflammation and fibrosis.

• AP3 enables precise matching of disease-driving pathways with drug mechanisms, leveraging AI-driven proteomics and proprietary tools for target identification and biomarker discovery.

• Headquarters in Boston with a proteomics hub in Medicon Valley, leveraging access to leading biotech clusters.

• Founded in 2018, IPO in 2022, and led by an accomplished team with deep expertise in drug development, clinical leadership, and business operations.

Pipeline and clinical programs

• Lead asset ACR-368 (CHK1/2 inhibitor) is in Phase 2b for endometrial cancer, with registrational intent arms and strong interim efficacy and safety data.

• ACR-2316 (WEE1/PKMYT1 inhibitor) is in Phase 1/2, showing potent single-agent activity and favorable safety in AP3-identified tumor types, including lung and ovarian cancers.

• CDKII inhibitor program is IND-enabling, with AML identified as a top indication and preclinical data showing complete tumor regression and synergy with BCL-2 inhibitors.

• Multiple internal programs and back-up series are advancing, with additional IND filings and clinical expansions planned for 2026–2027.

Clinical data and competitive positioning

• ACR-368 demonstrated a 52% ORR in serous endometrial cancer with ≤2 prior lines of therapy, significantly outperforming historical controls (13% ORR, 3.6 months PFS).

• Favorable safety profile for both ACR-368 and ACR-2316, with mainly transient hematological AEs and absence of severe non-hematological toxicities.

• AP3-driven OncoSignature biomarker enables prospective patient selection and response prediction, improving trial efficiency and therapeutic targeting.

• Strong preclinical synergy of ACR-368 and ACR-2316 with immune checkpoint inhibitors and topoisomerase I payload ADCs, supporting combination strategies.